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J. De Haro
Department of Angiology and Vascular Surgery, Hospital Universitario Getafe, Madrid, SpainHas it never happened to you that a good intention
ended up being harmful? Nguyen et al.1 have demon-
strated the association between the intensity on mag-
netic resonance imaging (MRI) and intra-aneurysm
thrombus and abdominal aorta aneurysm (AAA) growth
rate. Their ﬁnding is interesting as it keeps pushing for-
ward the knowledge of aneurysm disease. Many others
have tried to ﬁgure out the risk markers of AAA growth/
rupture. The scope, magnitude, multicity, and spread of
such potential studied markers is highly varied.2,3 So far, a
method for predicting AAA growth and rupture remains
elusive, and a reliable parameter to identify those pa-
tients who will beneﬁt from early AAA repair is lacking.
We completely agree with the Maastricht group2 when
they state that an ideal marker should have a causal rela-
tionship to the relevant disease, be involved in all the
pathophysiological pathways, and reﬂect disease severity
and progression by its measurement, or all three. Further-
more, the biomarker should be sensitive to intervention.
The group claims, and we agree, that the validation of such
markers should rely on the basic principles of biological
plausibility, correlation with epidemiological studies, and
clinical relevance and treatment effects on the biomarker.
However, none of the candidates (including the last one,
the high thrombus signal intensity from Nguyen) has yet
met the triad of marker/surrogate criteria. It is not possible,
so far, to use them as an AAA diagnostic tool.
The ﬁrst requirement is that candidates have a conclu-
sive statistical association with the expansion rate.
Furthermore, they must prove a linear correlation. It must
be said that in no case do the candidates meet this con-
dition. Any mathematical inconsistency, disparity of data
between different publications, suspicion of bias (i.e.
selection bias due to small sample size), and any weak
correlation invalidate such factors as reliable and individual
predictors of AAA progression.
Such details as the sample representativeness (i.e. in-
consistencies in the expected relationship between cross-DOI of original article: http://dx.doi.org/10.1016/j.ejvs.2014.04.025
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and grouping method for statistical analysis deserve special
mention. They could be milestones when rejecting the
factor as an independent marker.
Therefore, authors intending that their candidate ach-
ieves risk marker status should place special emphasis on
clear questions about the statistical association between
the variables. Potential confounding factors should be
minimized, thoroughly controlling all those that are known.
Adjustment for initial AAA size, age, smoking history, and
measurement error for determination of AAA size should be
taken into account, without exception.2
The diameter of the AAA, not the cross-sectional area, is
a true surrogate marker of the growth rate,4 which reﬂects
the magnitude of the degenerative process of the wall, and
is thus also a surrogate marker of rupture. To date, AAA size
is considered the gold standard for clinical prediction of risk.
It is well known as an independent factor inﬂuencing AAA
growth. Active investigations to identify markers other than
size should relate the data to this confounding factor.
The technical features of such a diagnostic tool are also
important; in particular, the measurement error for deter-
mination of AAA size, the method of sampling, and the
quality of the candidate marker data assessment should be
considered. Furthermore, the assay should be standardized
and of a high quality to achieve reproducible results.
Unique determinations of the candidate marker should be
avoided.
The coefﬁcient of variation (calculated as the standard
deviation divided by the mean) of the determination of AAA
near to 25% is close to unacceptable for establishing any
solid statistical association. Likewise, highly dispersed as-
sessments leading to an approximate or above 50% (even
not claimed) coefﬁcient of variation in the candidate marker
(both in the main analysis and reproducibility test) minimise
the conclusions that may be drawn from these studies.
It should not be ruled that inconsistencies in expected
outcomes (i.e., disparate and poorly justiﬁable results
among the study groups, under the preliminary hypothesis)
involves a lack of plausibility. It is not uncommon that any
such candidates actually concern an epiphenomenon.
Moreover, although some studies of those markers have
shown promising results, they have not yet led to a clinically
686 J. De Haroapplicable marker. The Nguyen1 study reports results that
will not have any inﬂuence in clinical practice as MRI is not,
and will not be, at least in the short-mid-term, a standard
tool for pre-operative AAA surveillance.5
To conclude, several potential markers for progression of
AAA have been investigated. Most show either no correla-
tion or weak correlation with the clinical course of the AAA.
Few have any potential for clinical use. Large accurately
designed and performed longitudinal observational studies
are necessary to assess the true potential of such markers.
Every detail counts.
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